近日，一场被寄予厚望的战略合作在扬州落地生根——江苏省苏北人民医院与苏州大学正式签约，并揭牌成立三个协同创新中心。这不仅是一场仪式，更是 区域医疗发展格局优化升级的关键一步，标志着苏北人民医院与顶尖高校的合作，从零散的点状交流，全面升维至体系化、战略性的融合发展新阶段。 人才自主培养能力升级：通过共建培养平台、共享导师资源，苏北人民医院在医学研究生培养、青年医师科研训练、骨干人才研修等方面将获得体系化支 持，为医院长期发展储备并孵化本土化高层次人才，形成可持续发展的核心动力。 对"健康扬州"：注入普惠于民、引领区域的强劲动能 签约仪式（扬州市卫生健康委员会供图） 超越签约：构建医教研协同发展的创新共同体 此次合作的核心，在于"深度融合"与"战略协同"。苏北人民医院院长王永祥表示，双方关系正迈向以人才培养为根基、学科建设为载体、科研转化为关键的 全面协作。这意味着，合作将直接触及医院高质量发展的核心要素：人与创新。 扬州市卫健委党委书记尹成雷指出，这是市校战略关系在卫生健康领域的重要深化。在"健康中国"与"健康扬州"的蓝图下，此次合作绝非简单叠加，而是旨 在通过机制性联动，将苏州大学在基础研究、学科前沿、人才培 ...

（来源：衢州日报） 转自：衢州日报 本报讯 （记者 腊莎 通讯员 姜丽） 近日，浙江省自然科学基金委员会办公室发布2026年度浙江省自然 科学基金自筹经费拟立项项目公示，衢州市第二人民医院（浙大二院衢州分院）申报的《胃肠道应激性 溃疡中高糖环境致免疫细胞代谢重编程的具体研究机制》项目成功入选，斩获立项支持。这是衢州二院 自建院以来首次摘得浙江省自然科学基金项目立项，标志着医院在科研攻关领域实现历史性"零的突 破"，为高质量发展注入强劲动能与崭新希望。 浙江省自然科学基金是全省支持基础研究、培育科技人才的核心平台，以高门槛、高竞争、高含金量著 称。此次项目成功突围，印证了衢州二院"医教研协同发展"战略的成效，体现了医院科研实力提升。 依托浙大二院协作资源及"山海"提升工程赋能，衢州二院将科研创新纳入战略重点。通过提前动员、专 家培训、多轮打磨申报材料等举措，医院科研申报质量持续提升，学术氛围日益浓厚。此次立项让全院 备受激励，成为科研发展的重要鞭策。 该项目聚焦临床常见的胃肠道应激性溃疡，探究高糖环境下免疫细胞代谢重编程机制。成果有望填补相 关基础研究空白，为疾病防治提供新思路与靶点，充分体现"从临床中来，到临 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Insights - The company's performance meets expectations with steady revenue growth. For the first three quarters of 2025, the operating revenue reached 3.272 billion yuan, a year-on-year increase of 2.83%. In the third quarter alone, the operating revenue was 1.133 billion yuan, growing by 0.13% year-on-year. The overall gross margin remains stable, with a gross margin of 44.71% in Q3 2025, slightly down from 45.44% in Q2 2025. Future growth in gross margin is anticipated as the company continues to focus on high-quality services, awaiting a return to higher revenue growth rates [5][11]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported an operating revenue of 3.272 billion yuan, up 2.83% year-on-year, and a net profit attributable to shareholders of 434 million yuan, an increase of 3.04%. In Q3 2025, the operating revenue was 1.133 billion yuan, with a net profit of 152 million yuan, down 2.37% year-on-year [5][11]. Strategic Initiatives - The company adheres to a dual-driven strategy of "internal growth + external mergers and acquisitions." It leverages the Xiamen Eye Center as a core, utilizing its leading diagnostic and treatment capabilities along with mature hospital management experience. The company has established a standardized high-quality medical service and management system across its chain of hospitals, expanding its ophthalmology network to 64 specialized hospitals and 67 optical centers across 19 provinces and municipalities by mid-2025 [11]. Research and Development - The company emphasizes the "coordinated development of medicine, education, and research," focusing on eye disease treatment. It has established a comprehensive medical education and research system, collaborating with over 40 universities, including Peking University and Xiamen University. This collaboration covers talent training, academic co-construction, and clinical research, with over 380 national and provincial research projects initiated and 1,641 academic papers published by mid-2025 [11]. Profit Forecast and Investment Advice - The company is projected to achieve net profits attributable to shareholders of 540 million yuan, 640 million yuan, and 730 million yuan for 2025, 2026, and 2027, respectively. The current stock price corresponds to price-to-earnings ratios of 30, 25, and 22 times for the respective years, maintaining a "Buy" rating [11].

Core Viewpoint - The company reported a stable performance in the first half of 2025, with a revenue of 2.139 billion and a net profit of 282 million, indicating a year-on-year growth of 4.31% and 6.20% respectively. The second quarter showed a slight decline in revenue but a significant increase in net profit [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 2.139 billion, a year-on-year increase of 4.31%, and a net profit of 282 million, up 6.20% [1]. - For Q2 2025, the company reported a revenue of 1.046 billion, a decrease of 2.47% year-on-year, while the net profit was 132 million, reflecting a growth of 20.73% [1]. Revenue Breakdown - The revenue from refractive projects reached 789 million, growing by 13.75% year-on-year [2]. - The revenue from comprehensive optometry projects was 514 million, an increase of 3.42% [2]. - The cataract project revenue was 431 million, showing a decline of 7.33% [2]. - The posterior segment project revenue was 277 million, with a growth of 5.52% [2]. Strategic Development - The company is focusing on a strategy of "internal growth + external mergers and acquisitions," having established 64 specialized eye hospitals and 67 optometry centers across 49 cities in 19 provinces and municipalities in China by mid-2025 [3]. - The company emphasizes talent development and collaboration with over 40 universities, including Peking University and Xiamen University, to enhance clinical research and training [3]. Profit Forecast - The projected net profits for the company from 2025 to 2027 are estimated to be 540 million, 640 million, and 720 million respectively, with corresponding price-to-earnings ratios of 32, 27, and 24 times [3].

Core Viewpoint - Huaxia Eye Hospital Group Co., Ltd. reported a revenue of 2.14 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 281.96 million yuan, up 6.20% from the previous year [10]. Financial Performance - The company's total assets reached 8.17 billion yuan, with net assets attributable to shareholders at 5.85 billion yuan, marking an increase of 3.08% and 0.91% respectively compared to the end of the previous year [10]. - Basic earnings per share increased to 0.34 yuan, a rise of 6.25% from 0.32 yuan in the same period last year [10]. Business Overview - The company operates as a large-scale eye care chain, providing comprehensive eye medical services including diagnosis and treatment of various eye diseases [10]. - Huaxia Eye Hospital Group emphasizes a mission to serve every patient regardless of their financial status, aiming to provide high-quality eye care services [10]. Service Offerings - The company specializes in eight major sub-disciplines of ophthalmology, including cataract, refractive surgery, retinal diseases, strabismus and amblyopia, and ocular surface diseases [10]. - Huaxia Eye Hospital Group has established a nationwide network of medical services, with a focus on both internal growth and external acquisitions to enhance its service capabilities [10]. Technological Advancements - The company has introduced advanced technologies and equipment in refractive surgery and cataract surgery, maintaining a leading position in the industry [11][12]. - Notable innovations include the introduction of the latest laser systems for cataract surgery and the development of new artificial lenses, enhancing surgical precision and patient outcomes [12]. Strategic Direction - The company plans to continue its strategy of "internal growth + external mergers and acquisitions," focusing on balanced development in medical services, education, and research [10]. - Future initiatives will aim to expand the national eye care network and improve service quality, ensuring accessibility and affordability for patients [10].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company's performance in 2024 met expectations, with total revenue of 4.027 billion yuan, a year-on-year increase of 0.35%. However, the net profit attributable to the parent company decreased by 35.63% to 429 million yuan [6][12]. - The revenue breakdown for 2024 shows a decline in cataract project revenue by 11.56% to 873 million yuan, while the revenue from refractive projects increased by 7.44% to 1.296 billion yuan. The overall growth slowdown is attributed to changes in the industry environment, a temporary slowdown in demand, and intensified competition [2][12]. - The company is advancing its strategic acquisitions to expand its ophthalmology service network, having established 62 specialized hospitals and 66 optical centers across 48 cities in China by 2024 [12]. - The company emphasizes clinical discipline development and quality improvement in medical services, with two top-tier ophthalmology hospitals supporting clinical diagnosis, research innovation, and talent cultivation [12]. - The company has formed a three-tiered research innovation platform system and has received approval for five new research innovation platforms in 2024, along with 60 new medical research projects [12]. - Profit forecasts for the company indicate net profits of 540 million, 640 million, and 720 million yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 29, 25, and 22 times [12]. Financial Summary - In 2024, the total revenue is projected at 4.027 billion yuan, with a gross profit of 1.780 billion yuan, resulting in a gross margin of 44% [17]. - The company expects to see a gradual increase in revenue and net profit over the next three years, with total revenue projected to reach 5.235 billion yuan by 2027 [17].